Cleared Traditional

K121679 - ACCU-CHEK INFORM II BLOOD GLUCOSE MONITORING SYSTEM

K121679 is an FDA 510(k) clearance for ACCU-CHEK INFORM II BLOOD GLUCOSE MONIT..., manufactured by Roche Diagnostics. The device is a Class 2 Chemistry device with product code NBW cleared through the Traditional 510(k) pathway after a 126-day FDA review.

K121679 · Roche Diagnostics · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2012
Decision
126d
Days
Class 2
Risk

K121679 is an FDA 510(k) clearance for the ACCU-CHEK INFORM II BLOOD GLUCOSE MONITORING SYSTEM. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Roche Diagnostics (Indianapolis, US). The FDA issued a Cleared decision on October 11, 2012 after a review of 126 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Roche Diagnostics devices

FDA 510(k) Submission Details - K121679

510(k) Number K121679 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 07, 2012
Decision Date October 11, 2012
Days to Decision 126 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
38d slower than avg
Panel avg: 88d · This submission: 126d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 309
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K121679.
ONETOUCH REVEAL DIABETES MANAGEMENT APPLICATION
K120558 · Lifescan, Inc. · Feb 2013
RIGHTEST BLOOD GLUCOSE MONITORING SYSTEM GM700 GE GE200 BLOOD GLUCOSE MONITORING SYSTEM RIGHTEST BLOOD GLUCOSE MONITORIN
K123008 · Bionime Corporation · Jan 2013
ON CALL VIVID BLOOD GLUCOSE MONITORING SYSTEM
K123010 · ACON Laboratories, Inc. · Dec 2012
BIOLAND G-423 GLOOD GLUCOSE MONITORING SYSTEM
K113077 · Taidoc Technology Corporation · Aug 2012
BIONIME RIGHTEST BLOOD GLUCOSE MONITORING SYSTEM, MODEL GM650
K120423 · Bionime Corporation · Aug 2012
HEALTHPRO BLOOD GLUCOSE MONITORING SYSTEM
K113192 · Infopia Co, Ltd. · Jul 2012